Sanofi Nigeria reinforces commitment to hypertension management through new treatment

L-R: Associate Professor of Medicine, University of Lagos, Dr. Amam Chinyere Mbakwem; Deputy Managing Director, Maayoit Healthcare Limited, Dr. Ademola Aderigbigbe; Chief Medical Director, LASUTH, Prof. Adewale Oke; Business Unit Head- Ethical Sanofi, Folake Odediran; Head Public Affairs Sanofi Mr. Oladimeji Agbolade; General Manager, Sanofi Nigeria-Ghana, Abderrahmane Chakibi; and Head of Medical and Regulatory, Sanofi Nigeria/Ghana, Dr. Inoussa Fiffen at the official launch of a new blood pressure control drug, by Sanofi Aventis at Oriental Hotels, Victoria Island on Wednesday, 17th June, 2015

With the introduction of APROVASC, a fixed-dose combination treatment for the management of hypertension, Sanofi reinforces its sustained commitment to healthcare through the provision of affordable medicines that are tailored to the needs of patients.

With APROVASC, Sanofi now offers a wide range of treatment options for patients with hypertension. To better support the patients in the management of their disease, Sanofi continues with its access to healthcare ambition in the opening of diabetes and hypertension clinics in partnership with health authorities. The first clinic was inaugurated at the Lagos State University Teaching Hospital (LASUTH) on 29th January 2015.

In Nigeria, about 28.9% of the population has raised blood pressure while about 82% are not aware of this disease condition. By 2030, up to 39.1 million people aged at least 20 years may live with hypertension1 if nothing is done to reverse the trend. People with uncontrolled hypertension are exposed to many complications including stroke, heart attack, kidney failure and problems with vision, which can be controlled by adopting healthy diets, lifestyle changes and, in many cases, treatment with medications.

With over 90 years’ experience in development and manufacturing, Sanofi is a world leader in delivering quality, innovative solutions to meet the needs of patients. The APROVASC® range offers dosage flexibility that allows for individualized treatment.

“By introducing a new antihypertensive treatment, Sanofi demonstrates its commitment to patients through improving access to high quality solutions in the field of hypertension management in Nigeria. APROVASC introduction is another example of Sanofi’s engagement to always provide advanced and innovative treatments in response to patients’ specific needs with the highest efficacy and comfort. This unique combination is the result of years of development, clinical studies and safety proofing” said Abderrahmane Chakibi, General Manager, Sanofi Nigeria-Ghana.

L-R: Chief Medical Director, LASUTH, Prof. Adewale Oke;, Business Unit Head- Ethical Sanofi, Mrs. Folake Odediran; Head Public Affairs Sanofi Mr. Oladimeji Agbolade; and General Manager, Sanofi Nigeria-Ghana, Abderrahmane Chakibiat the official launch of a new blood pressure control drug, Aprovasc by Sanofi Aventis at Oriental Hotels, Victoria Island

“Delivering innovative treatments and a full portfolio adapted to the needs of patients locally is at the core of what we, at Sanofi, have done for nearly a century. But medications alone are not enough. For many years, we have been supporting healthcare professionals in their daily practice through training and other tailored services. Through leveraging APROVASC® availability in Nigeria, Sanofi will continue to contribute to making the lives of Nigerian hypertensive patients healthier” Mr. Chakibi added.